For the molecular markers in CRC, the mutation rates of MSI-H, KRAS, and NRAS were reported to be 6-15% (Horvat and Stabuc, 2011; Gelsomino et al., 2016; Chang et al., 2017; Samstein and Chan, 2017), 38.5-40% (Natsume et al., 2018), and 1-6% respectively (Downward, 2003). Here, KRAS is linked to colorectal carcinoma.